Human Growth Hormone
Human Growth Hormone, or HGH, is a hormone that is naturally produced by the pituitary gland, a small gland located at the base of the brain. HGH acts as a catalyst for many glandular secretions and life functions critical to maintaining wellness. It fuels growth during childhood, promotes healthy metabolism, and continues to maintain tissues and organs throughout life.
Age Related HGH Production Decline
As early as your 40s, HGH production starts a slow decline. This decrease in HGH production is even more dramatic in people who have had a minor or traumatic brain injury, pituitary tumors, and radiation or surgery to the pituitary gland.
Critical symptoms of hgh decline
- Mental Confusion
- Decreased Immunity
- Cardiovascular problems
Human Growth Hormone Replacement Therapy
HGH Replacement therapy has achieved significant results in reducing the deficiency symptoms of depleting HGH levels.
Mayo Clinic studies have shown that injections of human growth hormone can improve the following:
- Increased bone density
- Increased muscle mass
- Decrease in body fat
- Bolster the heart’s ability to contract
- Improve mood
- Increase capacity to exercise
- Overall effects reported was a stronger body with fewer negative age-related symptoms
HGH treatment usually takes weeks before the first improvements appear. In generally most of the improvements are noticed in the 2nd through 4th months and many patients continue to improve for 2-3 years after the initiation of treatment. HGH is contraindicated in patients with active malignancy, benign intracranial hypertension and proliferative retinopathy. HGH is not recommended during pregnancy.
At Regeneveda, we help combat human growth hormone deficiency with effective HGH hormone replacement therapy. When administered to patients diagnosed with adult human growth hormone deficiency, (its only legal indication for use), the symptoms of deficiency can be significantly improved. Dr. Lobe is an expert injector who teaches injection therapies to physicians from around the world. Correct diagnosis and your own personalized treatment plan are critical.
Learn more about hormone replacement therapy
Cancer Risk and HGH Treatment
Since HGH makes tissues grow, there is some theoretical concern whether HGH could increase the risk of cancer. In children taking HGH, no significant increased risk of cancer has been seen (even in leukemia and lymphoma). In children with brain tumors, HGH treatment reduced the 5-yr mortality rate by 50% and the brain tumor recurrence rate by 40%. In patients with advanced gastrointestinal cancers treated with HGH injections, the duration of survival was increased by months while the recurrence and remission period were significantly increased. A study of more that 1000 patients with acromegaly (HGH excess) showed that the overall cancer incidence was lower than the general population. This included breast and prostate cancer. Some studies on acromegalic patients showed an increase in the incidence of colon cancer. However, the IGF-1 levels in these patients are extremely high, far above what we see with physiological doses of HGH. And, the HGH in acromegaly may be 10-100 times the normal daily production.
Studies on acromegalic patients appear to support an increased incidence of prostate cancer that was observed in one 6th of the studies in men with high IGF-1 levels and an increase in breast cancer observed in about half of the studies of woman with high IGF-1 levels. To confuse matters, another 6th of the studies in men show that high IGF-1 levels are protective against prostate cancer and the rest of the studies showed no influence. Animal studies suggest that the high IGF-1 levels are due to the cancer and are not causative. And malignant breast cancers are IGF-1 resistant, suggesting that it is unlikely that the IGF-1 caused the cancer. On the contrary, high IGF-1 levels may be protective. Patients who are clinically human growth hormone deficient have a higher risk and incidence of cancer up to 2-5 times normal, and HGH treatment reduces this risk by half in all forms of cancer except for GI tumors. Anecdotal reports of HGH treatment in terminal cancer patients also support a protective effect. The data demonstrates that not only is there an improved quality of life in these patients but their survival is longer and the HGH slows the progression of the disease. While anecdotal reports are not significant, there is little evidence that HGH is harmful at the low physiological doses we recommend and support. Furthermore, HGH is a powerful stimulator of the immune system, an effect that may help to prevent and even treat cancer.